Program
bimagrumab
Also written as “Bimagrumab”, “BYM338” and “LY3985863”.
Its studies are mostly in Myositis, Inclusion Body · Obesity · Sarcopenia · Cachexia · Heart Failure, Diastolic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 120 open or running | phase 3since Aug 15, 2013 | Aug 12, 2011 | none ahead |
| Eli Lilly | 62 open or running | phase 2since Oct 16, 2022 | Oct 16, 2022 | Jul 2029phase 2 · NCT07920887 |
- Named in Eli Lilly’s own pipeline as
Bimagrumab
, phase 2, as of Oct 29, 2026 (source).
Also a collaborator on its studies: versanis-bio-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Aug 12, 2011.
- Apr 12, 2013Phase 2 study in CachexiaNovartis · NCT01868685
- Aug 15, 2013Phase 3 study in Myositis, Inclusion BodyNovartis · NCT01925209 · 251 enrolled · United States, Australia, Belgium and more
- Mar 20, 2014Phase 3 study in Myositis, Inclusion BodyNovartis · NCT02250443 · 10 enrolled · United States
- May 8, 2014Phase 2 study in Muscular AtrophyNovartis · NCT02152761 · 251 enrolled · United States, Argentina, Australia and more
- Dec 10, 2014Phase 2 study in SarcopeniaNovartis · NCT02333331 · 217 enrolled · United States, Australia, Belgium and more
- Apr 30, 2015Phase 2 study in SarcopeniaNovartis · NCT02468674 · 160 enrolled · United States, Australia, Belgium and more
- Jul 9, 2015Phase 3 study in Myositis, Inclusion BodyNovartis · NCT02573467 · 211 enrolled · United States, Australia, Belgium and more
- Dec 24, 2016Phase 2 study in Diabetes Mellitus, Type 2Novartis · NCT03005288 · 78 enrolled · United States, United Kingdom
- Oct 16, 2022Eli Lilly's first study: phase 2 study in ObesityNew to Eli LillyEli Lilly · NCT05616013 · 507 enrolled · United States, Australia, New Zealand
- Oct 14, 2024Phase 2 study in ObesityEli Lilly · NCT06643728 · 252 enrolled · United States
- Mar 18, 2025Phase 1 study in HealthyEli Lilly · NCT06890611 · 125 enrolled · United States
- Mar 24, 2025Phase 2 study in ObesityEli Lilly · NCT06901349 · United States, Argentina, Canada and more
- Jun 12, 2025Phase 1 study in HealthyEli Lilly · NCT07030127 · 24 enrolled · China
- Oct 29, 2026Phase 2 study in Heart Failure, DiastolicEli Lilly · NCT07920887 · 540 planned · United States, Hungary, Italy and more
Ahead
- Jul 2029Primary completion: phase 2 study in Heart Failure, DiastolicEli Lilly · NCT07920887
TargetBeta
“A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and …”NCIt, read by Claude
“Activin receptor type-2B antagonist”ChEMBL 37, by rule
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07920887Heart Failure, Diastolic · United States, Hungary, Italy and more | 2 | Not yet recruiting | Eli Lilly | Jul 2029 | 540 |
| NCT07030127Healthy · China | 1 | Completed | Eli Lilly | Feb 24, 2026 | 24 |
| NCT06901349Obesity · United States, Argentina, Canada and more | 2 | Withdrawn | Eli Lilly | Jun 10, 2025 | 0 |
| NCT06890611Healthy · United States | 1 | Completed | Eli Lilly | Sep 26, 2025 | 125 |
| NCT06643728Obesity · United States | 2 | Active, not recruiting | Eli Lilly | Jan 16, 2026 | 252 |
| NCT05616013Obesity · United States, Australia, New Zealand | 2 | Completed | Eli Lilly | May 16, 2024 | 507 |
| NCT03005288Diabetes Mellitus, Type 2 · United States, United Kingdom | 2 | Completed | Novartis | Mar 21, 2019 | 78 |
| NCT02573467Myositis, Inclusion Body · United States, Australia, Belgium and more | 3 | Completed | Novartis | Aug 17, 2016 | 211 |
| NCT02468674Sarcopenia · United States, Australia, Belgium and more | 2 | Completed | Novartis | Dec 3, 2018 | 160 |
| NCT02333331Sarcopenia · United States, Australia, Belgium and more | 2 | Completed | Novartis | Jun 26, 2018 | 217 |
| NCT02152761Muscular Atrophy · United States, Argentina, Australia and more | 2 | Completed | Novartis | May 14, 2018 | 251 |
| NCT02250443Myositis, Inclusion Body · United States | 3 | Completed | Novartis | Aug 23, 2016 | 10 |
| NCT01925209Myositis, Inclusion Body · United States, Australia, Belgium and more | 3 | Completed | Novartis | Jan 6, 2016 | 251 |
| NCT01868685Cachexia | 2 | Withdrawn | Novartis | Jan 2015 | 0 |
| NCT01669174Pulmonary Disease, Chronic Obstructive · United States, Netherlands, United Kingdom | 2 | Completed | Novartis | Dec 2014 | 67 |
| NCT01601600Skeletal Muscle · United States | 2 | Completed | Novartis | Dec 2013 | 40 |
| NCT01433263Cachexia · United States, Lithuania, Romania and more | 2 | Completed | Novartis | Apr 2014 | 57 |
| NCT01423110Myositis, Inclusion Body · United States | 2 | Completed | Novartis | May 2012 | 14 |
How it is read
Names in the registry
- “Bimagrumab”, 6 entries
- “BYM338”, 4 entries
- “bimagrumab”, 3 entries
- “LY3985863”, 1 entry
- “BYM338 10 mg/kg”, 1 entry
Codes read as this program: LY3985863.
Conditions, from the studies’ own filings
- Myositis, Inclusion Body, 4 studies
- Obesity, 3 studies
- Sarcopenia, 2 studies
- Cachexia, 2 studies
- Heart Failure, Diastolic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.